AMLXAmylyx Pharmaceuticals, Inc.

$28.14+111% 1Y

$28.14

$11.3852 weeks$39.67

The financials

Amylyx Pharmaceuticals, Inc. by the numbers

For the full year FY2025, revenue was $0 (−100% year on year) and net income −$145M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.

Amylyx Pharmaceuticals, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statement	Q2 2026	Q2 2025	Change
Revenue	n/a	$0	n/a
Gross profit	n/a	$0	n/a
Operating income	−$46M	−$43M	n/a
Net income	−$43M	−$41M	n/a
Diluted EPS	−$0.39	−$0.46	n/a

On our screens:Most shorted stocks

Drug Manufacturers, Specialty & Generic

Ranks #39 of 41 by RyuScore

Compare peers

BHC+0.08%

Bausch Health Companies Inc.

ANIP+2.6%

ANI Pharmaceuticals, Inc.

HCM+2.5%

HUTCHMED (China) Limited

PBH+0.77%

Prestige Consumer Healthcare Inc.

HROW-3.8%

Harrow, Inc.

ETON+0.75%

Eton Pharmaceuticals, Inc.